Landos Biopharma, Inc. (LABP)
| Market Cap | 608.58M |
| Revenue (ttm) | 18.00M |
| Net Income (ttm) | n/a |
| Shares Out | 40.12M |
| EPS (ttm) | -1.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 204,923 |
| Open | 15.10 |
| Previous Close | 15.27 |
| Day's Range | 14.65 - 15.55 |
| 52-Week Range | 8.82 - 16.99 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 25.50 (+64.1%) |
| Est. Earnings Date | Oct 28, 2021 |
About LABP
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory ...
Financial Performance
Financial StatementsNews
Landos Biopharma to Participate in Two Upcoming Investor Conferences in September
BLACKSBURG, Va., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel or...
Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins Uni...
BLACKSBURG, Va., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel ora...
Landos Biopharma to Participate in Upcoming Investor Events
BLACKSBURG, Va., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to develop novel ora...
Landos Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Updates
Following the recent positive End-of-Phase 2 meeting with the FDA, Landos initiated global pivotal Phase 3 clinical trial site feasibility studies of omilancor in ulcerative colitis (UC)
Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference
BLACKSBURG, Va., June 14, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and devel...
Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate ...
The FDA clears the path to initiate the PACIFY I and II global registration studies in Mild-to-Moderate Active UC patients representing the potential for a broad product label for Omilancor The FDA clea...
Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference
BLACKSBURG, Va., May 25, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE A.I. platform to discover and develop novel o...
Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors
BLACKSBURG, Va., May 19, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients w...
Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China
Landos Biopharma Inc (NASDAQ: LABP) and LianBio have announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China (mainlan...
Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates
Completed initial public offering of common stock, raising approximately $100 million in gross proceeds
Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 20...
BLACKSBURG, Va., April 26, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with...
Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors
BLACKSBURG, Va., April 13, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with...
Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation
The FDA has signed off Landos Biopharma's (NASDAQ: LABP) Investigational New Drug application for omilancor (BT-11) for the treatment of Eosinophilic Esophagitis (EoE). Landos expects to initiate patien...
Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis
Third potential indication for omilancor (BT-11), a first-in-class candidate for the treatment of autoimmune diseases Third potential indication for omilancor (BT-11), a first-in-class candidate for the...
Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers
NX-13 was well tolerated with no reported serious adverse events
Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with ...
Landos Biopharma Announces Pricing of Initial Public Offering
BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune dise...
Landos Biopharma guns for a $100M IPO to boost AI autoimmune R&D work
Xontogeny’s Landos Biopharma is jumping into warm biotech IPO waters as it looks to go public with a $100 million offering.
Will Murky Trial Data Undercut Landos' $100 Million IPO Launch?
On January 4, the company announced slightly murky data from its first-in-patients 12-week Phase II proof-of-concept trial of BT-11 for mild to moderate ulcerative colitis.
Autoimmune biotech Landos Biopharma files for a $100 million IPO
Landos Biopharma, a Phase 2 biotech developing oral small molecule therapies for autoimmune diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Landos Biopharma IPO Registration Document (S-1)
Landos Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.